Bispecific Antibodies in Solid Tumors: Advances and Challenges

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Bispecific antibodies (BsAbs) are engineered proteins that bind two distinct antigens, enabling novel therapeutic mechanisms in cancer immunotherapy.
• While BsAbs have achieved success in hematological malignancies, their application in solid tumors has faced challenges but is rapidly advancing.

Purpose of the Study:

• To review the mechanism of action of BsAbs in cancer treatment.
• To provide an overview of currently approved and developing BsAbs for solid tumors.
• To discuss challenges, toxicity management, and future directions for BsAbs in solid tumor therapy.

Main Methods:

• Literature review of bispecific antibody mechanisms, approved therapies, and ongoing clinical trials.
• Analysis of regulatory approvals (FDA and China) for BsAbs in solid tumors.
• Synthesis of information on clinical development, challenges, and future prospects.

Main Results:

• Five BsAbs (amivantamab, tarlatamab, tebentafusp, zanidatamab, zenocutuzumab) are FDA-approved for solid tumors; two (cadonilimab, ivonescimab) are approved in China.
• Numerous BsAbs are in early-phase clinical development for solid tumors, indicating significant ongoing research.
• Challenges in clinical use and toxicity management are critical considerations for BsAb therapy.

Conclusions:

• BsAbs represent a significant advancement in cancer immunotherapy, with growing efficacy in solid tumors.
• Continued research and development are crucial for overcoming challenges and expanding the therapeutic potential of BsAbs.
• Future directions focus on optimizing BsAb design, clinical application, and patient management for solid malignancies.